Wells Fargo & Company Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective cut by Wells Fargo & Company from $377.00 to $316.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 54.83% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Truist Financial cut their target price on Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Bank of America lowered their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 25th. Chardan Capital reiterated a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $434.57.

Alnylam Pharmaceuticals Trading Down 0.7%

NASDAQ ALNY traded down $1.39 during trading hours on Friday, hitting $204.09. 897,811 shares of the company were exchanged, compared to its average volume of 1,355,733. The stock has a 50-day moving average price of $289.80 and a 200 day moving average price of $312.07. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals has a 52 week low of $197.81 and a 52 week high of $495.55. The stock has a market cap of $27.25 billion, a PE ratio of 55.63 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.44) earnings per share. Analysts forecast that Alnylam Pharmaceuticals will post 7.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.86% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. First Horizon Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 20.7% in the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 28 shares in the last quarter. Yousif Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 29 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after acquiring an additional 35 shares in the last quarter. Golden State Wealth Management LLC lifted its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its position in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after acquiring an additional 38 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter revenue of approximately $1.29 billion, up 66.9% year over year, while adjusted earnings of $1.84 per share exceeded some analyst estimates. The company also highlighted continued strength across its transthyretin (TTR) franchise. Alnylam second-quarter earnings report
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating and set a $425 price target, while Needham maintained a “buy” rating with a revised $357 target. These targets imply substantial potential upside if Alnylam executes on its pipeline and commercial plans. Analyst rating reports
• Neutral Sentiment: Alnylam’s earnings performance was mixed: quarterly profit improved substantially from the prior year, but reported revenue of about $1.29 billion fell short of the roughly $1.32 billion consensus estimate in several reports. Alnylam second-quarter earnings results
• Negative Sentiment: The primary catalyst for the selloff was Alnylam’s reduction of its fiscal 2026 outlook. Product-revenue guidance was lowered to approximately $5.3 billion-$5.7 billion, reflecting slower-than-anticipated demand normalization for second-line Amvuttra and headwinds affecting the ATTR cardiomyopathy market. Fierce Pharma report on Amvuttra and guidance
• Negative Sentiment: The outlook cut raised concerns about the pace and durability of Amvuttra growth, Alnylam’s key commercial product. Multiple reports characterized the shares’ decline as a reaction to the weaker ATTR outlook and second-quarter revenue miss. MarketWatch report on Alnylam guidance
• Negative Sentiment: Several law firms announced securities-fraud investigations seeking investors who suffered losses. These announcements are often solicited investigations rather than evidence of wrongdoing, but they add reputational and legal overhang to the stock. Alnylam securities-fraud investigation announcement

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.